中文
About Us
About Us
Green Valley is an innovative Chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
About Green Valley
Our Business
Mission & Vision
Our Culture
Code of Business Ethics
GV-971
GV-971
Here you can get access to more information of GV-971.
Products
News Reports
Research Highlights
Milestones
Scientific Research Information
Scientific Research Information
Originality is the soul of our innovation in scientific research. We are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
Life Sciences Innovation
Research Parteners
News
News
Here you can get access to the latest news reports of Green Valley.
Press Releases
News Reports
Social Responsibility
Careers
Careers
Apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. We respect, appreciate and reward the contributions of every employee for their hard work and dedication.
Job Search
Salary and Benefits
Contact Us
Contact Us
Media Contacts
CN
Milestones
Milestones
Products
News Reports
Research Highlights
Milestones
Products
News Reports
Research Highlights
Milestones
Milestones of Oligomannate (GV-971) Development
1997
2006
2007
2009
2013
2014
2018
2019
2020
2021
2022

The research team led by Prof. Meiyu Geng found the potential carbohydrate compound with drug activity.


Clinical trial registration was completed in China on July, 2006


Launched phase I clinical study in China on December, 2007


 Green Valley acquired licensing rights for development of GV-971.


 GV-971 Phase II clinical trial was accomplished on August.


In 2014, the phase 3 clinical trial was conducted in 34 tier-1 hospitals in China led by Shanghai Jiaotong University Medical School Mental Health Center and Peking Union Hospital, with 818 patients completed the study. The trial was conducted in collaboration with IQVIA (formally Quintiles) and Bracket among other partners.
The ground-breaking of carbohydrate drug manufacturing site in Laoning Province, China, marks a significant milestone for Green Valley’s further development of carbohydrate drug innovation.


Completed phase III clinical trial on July, 2018.
Submitted new drug applications and market authorization to the National Medical Products Administration (NMPA) and Phase 3 clinical trial data was disclosed at the conference of 11th Clinical Trials on Alzheimer's Disease (CTAD) for the first time by Professor Meiyu Geng on October, 2018.
Center for Drug Evaluation, NMPA accepted the application of new drug on November, 2018


Findings of mechanisms of action study were published on the peer-review journal Cell Research as cover story.

GV-971 was approved conditionally by NMPA on November.

GV-971 officially launched the Chinese market on December.

GV-971 received approval by FDA on the IND application for a global multi-center Phase III clinical study on April.

GV-971 received approval by FDA on the IND application for a global multi-center Phase III clinical trial on April and kicked off patient-enrollment process on October.

GV-971 Global Phase III Clinical Trial completed first patient dosed globally on February, initiated in Greater China on May, and completed first patient dosed in Greater China on August.


GV-971 Gets Included in China National Reimbursement Drug List.